http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-102005054909-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a33b93701dc73916427205c684469af2 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| filingDate | 2005-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17fbb99121f236ed13e641d483321c58 |
| publicationDate | 2007-07-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | DE-102005054909-A1 |
| titleOfInvention | Nucleophosmin / B23 binding peptide to inhibit tumor growth and to regulate the transcriptional activity of p53 |
| abstract | ThenRev peptide, which binds to nucleophosmin / B23 with the highest affinity,nhas the highest cytotoxicity for Ras-3T3 cellsnon and inhibits tumor growth in nude mice most efficiently. The efficiencynColony formation of Ras-3T3 cells in soft agar becomes significantninhibited by treatment with the Rev peptide. In addition, cannthe Rev peptide both the doxorubicin induced decrease innCell viabilitynof U1 bladder cancer cells as well as the inhibition of tumor growthnin nude micenstrengthen.nTreatment with the Rev peptide increases protein expression andntranscriptional activitynof p53 and inhibits nucleophosmin / B23 mediated PCNA promoter activity. peptidesnthe high affinitynto have molecular targets like nucleophosmin / B23 provide onenvaluable approach fornAntikrebstherapeutika dar. |
| priorityDate | 2005-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 502.